Structure-Based Drug Design 2014
CHI's Fourteenth Annual Structure-Based Drug Design Conference - Overview
Experimental methods such as X-ray crystallography, NMR, and computational chemistry techniques have led to a better understanding and larger knowledge base of 3-dimensional structures and binding events, encouraging rapid development of structure-based drug design. Cambridge Healthtech Institute’s Fourteenth Annual Structure-Based Drug Design event will showcase informative, high-quality case studies, innovative techniques, and strategies to move from computation to experiment, and finally, to drug. Top scientists from pharma and biotech will address how they are hitting epigenetic targets, provide updates on the newest wave of GPCRs and other membrane proteins, and discuss the latest in fragment-based drug design. Attendees will return to their organizations with fresh perspectives and new ideas to maximize productivity and increase successes in drug discovery.
Chas Bountra, Ph.D.
Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford
What’s New This Year:
Hear up-to-the-minute case studies from: